New mechanisms of action for tissue-type plasminogen activator?  by Jaffe, Allan S.
132
Editorial Comment
New Mechanisms of Action
for Tissue-Type
Plasminogen Activator?*
ALLAN S. JAFFE, MD
St. Louis, Missouri
In the 2 years since the first description of the effects of
tissue plasminogen activator (t-PA) in patients (1), it has
emerged as the drug of choice for the treatment of patients
with acute myocardial infarction who require fibrinolysis.
In this issue of the Journal, Darius et al. (2) present data
that suggest that t-PA may influence the development of
myocardial necrosis by mechanisms other than Its well doc-
umented ability to lyse coronary thrombi. They report a
38% reduction (47 ± 4 to 23.9 ± 4%) in the percent of
the risk area that develops necrosis in a cat model in which
occlusion is induced by tightening a ligature and reperfusion
by loosening it (2). These results potentially have important
implications for the long-term use of t-PA.
Possible limitations of the study. Certain experimental
caveats need to be appreciated. It is possible that the effects
observed are unique to the melanoma-derivedactivator, unique
to cats, unique to low doses of activator because the amounts
used in this investigation are lower than those usually used
to achieve fibrinolysis or that the benefit observed occurs
only during a very narrow time window after ischemia . A
more important experimental question concerns the use of
tetrazolium stains for the assessment of infarct size. Many
questions remain concerning the mechanism by which these
agents delineate myocardial injury (3) and there are few data
validating this approach in models of occlusion followed by
very early reperfusion. The loss of reduced coenzymes (for
example, NADH), which are critical for the identification
of infarction with tetrazolium stains (3), could occur after
occlusion and reperfusion because of the prolonged meta-
bolic derangements in high energy phosphate stores known
as "metabolic stunning" that occur after occlusion and early
reperfusion (4). Thus, t-PA, either directly or by improving
the time course or extent of reperfusion, may have reduced
stunning rather than actual infarction . Alternatively, the os-
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motic effects of a t-PA infusion may inhibit the swelling
associated with cellular injury and thus delay the loss of
coenzymes. This possibility could be excluded by the eval-
uation of the effects of an inactivated solution of t-PA in
this experimental model. In each case , measurements after
more prolonged reperfusion (24 to 48 hours) may have re-
vealed the lack of a difference between treated and control
animals . Thus , these findings need to be confirmed after
more prolonged intervals of reperfiJsion and with additional
methods (for example, creatine kinase depletion) to quantify
the extent of necrosis.
Mechanisms for myocardial salvage. The enhanced
myocardial salvage observed by Bergmann et al. (5) with
positron tomography with t-PA compared with streptokinase
and cited by Darius was probably due, in large part, to more
rapid fibrinolysis with t-PA. The potential mechanisms re-
sponsible for the extensive myocardial salvage induced by
t-PA in this study are unclear. Although minor changes in
the rate-pressure product , which could be cumulative over
time were observed, these changes are unlikely to explain
the marked changes observed . The creatine kinase data and
experiments on isolated normal coronary arteries add little
to explain the possible beneficial effects of t-PA. A large
number of possible explanations exist: I) t-PA may affect
the adequacy of reperfusion by influencing vasomotion or
thrombus formation in large epicardial coronary arteries that
may be damaged during occlusion by the ligature; 2) t-PA
may have influenced smaller collateral vessels or inhibited
circulating products such as platelets, red cells or white cells
that may be responsible for reducing the adequacy of re-
perfusion in small vessels (the no reflow phenomenon); 3)
t-PA could have effects on the release of intramyocardial
catecholamines, which may be important, because both al-
pha- and beta-blockade have been shown to reduce the extent
of necrosis after reperfusion; and 4) these beneficial effects
oft-PA could be due to a direct protective effect on ischemic
tissue during reperfiJsion. At present , inhibition of calcium
influx and inhibition of the production of oxygen free rad-
icals or a combination of both, are the most attractive mech-
anisms being evaluated .
Clinical implications. It is difficult to anticipate the
clinical impact of these experimental findings, particularly
when the mechanisms are unknown . If t-PA reduces the
ultimate extent of necrosis after more prolonged intervals
of reperfusion by mechanisms other than lysis of coronary
thrombi in epicardial or intramural coronary arteries, the
implications are profound. Substantial efforts are now being
focused on the use of pharmacologic agents that may protect
ischemic myocardium before or during fibrinolysis , in an
attempt to enhance myocardial salvage . Most of these ex-
perimental studies have evaluated the effects of beta-adre-
nergic blocking agents , calcium channel blockers (6) and
alpha-adrenergic blocking agents with reperfusion (7). As
pointed out by Darius et al., streptokinase may also have
additional effects because it reduces nucleoside and lactic
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dehydrogenase depletion and improves ventricular function
in isolated perfused heart preparations (8 ,9) . It is unclear
whether these protective effects are mediated by the same
mechani sms as those reported for t-PA. Can we be confident
that the pharmacologic agents being investigated to improve
salvage during thrombolysis will be synergistic with the
potential protective effects of t-PA , or will the effects be
antagonistic?
The issue poses a major dilemma for modem day car-
diology. In an atmosphere where the rapid translation of a
laboratory finding into the clinical arena is the rule, state-
ments urging caution or further investigation before imple-
mentation are rarely viewed favorably, even when they are
prudent. Right or wrong, these findings should remind us
of how little we know about the pharmacology of fibrinolysis
and myocardial salvage and reinforce the need for solid
experimental confirmation before embarking on clinical in-
vestigation .
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